Since mutant Rac1 is specifically expressed on cancer cells and is important for the perpetual growth and survival of tumor cells, it is a promising target candidate for TCR gene therapy, a methodology that equips patient T cells with anti-cancer specificity. The gene discussed is RAC1; the disease is neoplasm.